Cargando…

The Complement Cascade as a Mediator of Human Malignant Hematopoietic Cell Trafficking

The complement cascade (ComC) cleavage fragments C3a and C5a regulate the trafficking of normal, differentiated hematopoietic cells, although they do not chemoattract more primitive hematopoietic stem/progenitor cells (HSPCs). By contrast, human myeloid and lymphoid leukemia cell lines and clonogeni...

Descripción completa

Detalles Bibliográficos
Autores principales: Lenkiewicz, Anna, Bujko, Kamila, Brzezniakiewicz-Janus, Katarzyna, Xu, Bing, Ratajczak, Mariusz Z.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6567995/
https://www.ncbi.nlm.nih.gov/pubmed/31231394
http://dx.doi.org/10.3389/fimmu.2019.01292
_version_ 1783427193903251456
author Lenkiewicz, Anna
Bujko, Kamila
Brzezniakiewicz-Janus, Katarzyna
Xu, Bing
Ratajczak, Mariusz Z.
author_facet Lenkiewicz, Anna
Bujko, Kamila
Brzezniakiewicz-Janus, Katarzyna
Xu, Bing
Ratajczak, Mariusz Z.
author_sort Lenkiewicz, Anna
collection PubMed
description The complement cascade (ComC) cleavage fragments C3a and C5a regulate the trafficking of normal, differentiated hematopoietic cells, although they do not chemoattract more primitive hematopoietic stem/progenitor cells (HSPCs). By contrast, human myeloid and lymphoid leukemia cell lines and clonogenic blasts from chronic myelogenous leukemia (CML) and acute myelogenous leukemia (AML) patients respond to C3 and C5 cleavage fragments by chemotaxis and increased adhesion. Consistent with this finding, C3a and C5a receptors are expressed by leukemic cells at the mRNA (RT-PCR) and protein (FACS) levels, and these cells respond to C3a and C5a stimulation by phosphorylation of p44/42 MAPK and AKT. However, neither of these ComC cleavage fragments have an effect on cell proliferation or survival. In parallel, we found that inducible heme oxygenase 1 (HO-1)–an anti-inflammatory enzyme, is a negative regulator of ComC-mediated trafficking of malignant cells and that stimulation of these cells by C3 or C5 cleavage fragments downregulates HO-1 expression in a p38 MAPK-dependent manner, rendering cells exposed to C3a or C5a more mobile. We propose that, while the ComC is not directly involved in the proliferation of malignant hematopoietic cells, its activation in leukemia/lymphoma patients (e.g., as a result of accompanying infections or sterile inflammation after radio-chemotherapy) enhances the motility of malignant cells and contributes to their dissemination in a p38 MAPK–HO-1 axis-dependent manner. Based on this idea, we propose that inhibition of p38 MAPK or upregulation of HO-1 by available small-molecule modulators would have a beneficial effect on ameliorating expansion and dissemination of leukemia/lymphoma cells in clinical situations in which the ComC becomes activated. Finally, since we detected expression of C3 and C5 mRNA in human leukemic cell lines, further study of the potential role of the complosome in regulating the behavior of these cells is needed.
format Online
Article
Text
id pubmed-6567995
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-65679952019-06-21 The Complement Cascade as a Mediator of Human Malignant Hematopoietic Cell Trafficking Lenkiewicz, Anna Bujko, Kamila Brzezniakiewicz-Janus, Katarzyna Xu, Bing Ratajczak, Mariusz Z. Front Immunol Immunology The complement cascade (ComC) cleavage fragments C3a and C5a regulate the trafficking of normal, differentiated hematopoietic cells, although they do not chemoattract more primitive hematopoietic stem/progenitor cells (HSPCs). By contrast, human myeloid and lymphoid leukemia cell lines and clonogenic blasts from chronic myelogenous leukemia (CML) and acute myelogenous leukemia (AML) patients respond to C3 and C5 cleavage fragments by chemotaxis and increased adhesion. Consistent with this finding, C3a and C5a receptors are expressed by leukemic cells at the mRNA (RT-PCR) and protein (FACS) levels, and these cells respond to C3a and C5a stimulation by phosphorylation of p44/42 MAPK and AKT. However, neither of these ComC cleavage fragments have an effect on cell proliferation or survival. In parallel, we found that inducible heme oxygenase 1 (HO-1)–an anti-inflammatory enzyme, is a negative regulator of ComC-mediated trafficking of malignant cells and that stimulation of these cells by C3 or C5 cleavage fragments downregulates HO-1 expression in a p38 MAPK-dependent manner, rendering cells exposed to C3a or C5a more mobile. We propose that, while the ComC is not directly involved in the proliferation of malignant hematopoietic cells, its activation in leukemia/lymphoma patients (e.g., as a result of accompanying infections or sterile inflammation after radio-chemotherapy) enhances the motility of malignant cells and contributes to their dissemination in a p38 MAPK–HO-1 axis-dependent manner. Based on this idea, we propose that inhibition of p38 MAPK or upregulation of HO-1 by available small-molecule modulators would have a beneficial effect on ameliorating expansion and dissemination of leukemia/lymphoma cells in clinical situations in which the ComC becomes activated. Finally, since we detected expression of C3 and C5 mRNA in human leukemic cell lines, further study of the potential role of the complosome in regulating the behavior of these cells is needed. Frontiers Media S.A. 2019-06-07 /pmc/articles/PMC6567995/ /pubmed/31231394 http://dx.doi.org/10.3389/fimmu.2019.01292 Text en Copyright © 2019 Lenkiewicz, Bujko, Brzezniakiewicz-Janus, Xu and Ratajczak. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Lenkiewicz, Anna
Bujko, Kamila
Brzezniakiewicz-Janus, Katarzyna
Xu, Bing
Ratajczak, Mariusz Z.
The Complement Cascade as a Mediator of Human Malignant Hematopoietic Cell Trafficking
title The Complement Cascade as a Mediator of Human Malignant Hematopoietic Cell Trafficking
title_full The Complement Cascade as a Mediator of Human Malignant Hematopoietic Cell Trafficking
title_fullStr The Complement Cascade as a Mediator of Human Malignant Hematopoietic Cell Trafficking
title_full_unstemmed The Complement Cascade as a Mediator of Human Malignant Hematopoietic Cell Trafficking
title_short The Complement Cascade as a Mediator of Human Malignant Hematopoietic Cell Trafficking
title_sort complement cascade as a mediator of human malignant hematopoietic cell trafficking
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6567995/
https://www.ncbi.nlm.nih.gov/pubmed/31231394
http://dx.doi.org/10.3389/fimmu.2019.01292
work_keys_str_mv AT lenkiewiczanna thecomplementcascadeasamediatorofhumanmalignanthematopoieticcelltrafficking
AT bujkokamila thecomplementcascadeasamediatorofhumanmalignanthematopoieticcelltrafficking
AT brzezniakiewiczjanuskatarzyna thecomplementcascadeasamediatorofhumanmalignanthematopoieticcelltrafficking
AT xubing thecomplementcascadeasamediatorofhumanmalignanthematopoieticcelltrafficking
AT ratajczakmariuszz thecomplementcascadeasamediatorofhumanmalignanthematopoieticcelltrafficking
AT lenkiewiczanna complementcascadeasamediatorofhumanmalignanthematopoieticcelltrafficking
AT bujkokamila complementcascadeasamediatorofhumanmalignanthematopoieticcelltrafficking
AT brzezniakiewiczjanuskatarzyna complementcascadeasamediatorofhumanmalignanthematopoieticcelltrafficking
AT xubing complementcascadeasamediatorofhumanmalignanthematopoieticcelltrafficking
AT ratajczakmariuszz complementcascadeasamediatorofhumanmalignanthematopoieticcelltrafficking